echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Hua Medicine Announces 2020 Annual Results

    Hua Medicine Announces 2020 Annual Results

    • Last Update: 2021-07-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com




    Drug pipeline progress in 2020

    • The seeding study was successfully completed.


      • Established a strategic cooperation with Bayer and reached a commercial cooperation agreement on Dozaglietin in China


        As of December 31, 2020, for the year

        • Bank balances and cash amounted to approximately RMB 1.


          • In the first half of 2021, it is planned to submit the NDA of dozagliflozin to the China National Medical Products Administration (NMPA)
            .
          • It is planned to carry out research on dozaglietin for diabetic nephropathy in the second half of 2021
            .
          • In the second half of 2021, it is planned to carry out more studies on the combination of dozaglietin, including the combination of GLP-1 inhibitors and insulin in patients with type 2 diabetes, and the study in patients with type 1 diabetes.
            Research on combination medication with insulin
            .
            Expand the clinical pipeline of fixed-dose compound preparations of dozaglietin
            .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.